Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

September 6, 2020

Primary Completion Date

October 6, 2020

Study Completion Date

December 6, 2020

Conditions
Covid19
Interventions
BIOLOGICAL

Administration of Equine immunoglobulin anti SARS-CoV-2

The participants will receive premedication with Acetaminophen 500mg PO, Cimetidine300mg IV and Chlortrimeton 10mg IV. Then the investigators will do the Administration of Equine Imunoglobulin anti SARS Cov 2 on day 1 a vial of 10ml of the drug during 1 hour Intravenously. Then the hospitalized participants will be followed until they are discharged.

Trial Locations (4)

Unknown

Centro Especializado de Atención COVID19 (CEACO), San José

Hospital Dr. Rafael Ángel Calderón Guardia, San José

Hospital México, San José

Hospital San Juan de Dios, San José

All Listed Sponsors
collaborator

Universidad de Costa Rica

OTHER

collaborator

Ministry of Health Costa Rica

UNKNOWN

lead

Caja Costarricense de Seguro Social

OTHER_GOV

NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients | Biotech Hunter | Biotech Hunter